Gilead and arcus biosciences complete closing of option exercise for three clinical-stage programs and new research collaboration

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced the closing of gilead's option exercises to three programs in arcus's clinical-stage portfolio and a new research collaboration between the two companies. on november 17, 2021, gilead exercised its options to anti-tigit molecules domvanalimab and ab308, as well as clinical candidates etrumadenant (dual adenosine a2a/a2b receptor antagonist) and qu
RCUS Ratings Summary
RCUS Quant Ranking